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The formation of cerebral senile plaques composed of amyloid b peptide (Ab) is a fundamental feature of Alzheimer’s
disease (AD). Glial cells and more speciﬁcally microglia become reactive in the presence of Ab. In a triple transgenic model of
AD (3 Tg-AD), we found a signiﬁcant increase in activated microglia at 12 (by 111%) and 18 (by 88%) months of age when
compared with non-transgenic (non-Tg) controls. This microglial activation correlated with Ab plaque formation, and the
activation in microglia was closely associated with Ab plaques and smaller Ab deposits. We also found a signiﬁcant increase in
the area density of resting microglia in 3 Tg-AD animals both at plaque-free stage (at 9 months by 105%) and after the
development of A plaques (at 12 months by 54% and at 18 months by 131%). Our results show for the ﬁrst time that the increase
in the density of resting microglia precedes both plaque formation and activation of microglia by extracellular Ab accumulation.
We suggest that AD pathology triggers a complex microglial reaction: at the initial stages of the disease the number of resting
microglia increases, as if in preparation for the ensuing activation in an attempt to ﬁght the extracellular Ab load that is
characteristic of the terminal stages of the disease.
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Microglial cells, which were discovered by Pio Del Rio Hortega,
1
are the resident macrophages of the CNS. These cells of
myeloid origin
2 enter the CNS shortly after birth, and dissemi-
nate over the brain and the spinal cord, where they rapidly
transform into the resting microglia with a peculiar morphologi-
cal appearance.
3The resting microglial cells have small somata
and multiple ﬁne processes, with each cell occupying the
deﬁned domain that does not overlap with the neighbouring
microglia. In the healthy CNS, microglial processes are on a
constant move, scanning the microenvironment in their
territorial domains.
4,5 Insults to the nervous system trigger a
complex and multi-stage activation of microglia,
6 which results
in both phenotypic and functional changes.
Being the intrinsic CNS defence system, microglia are
intimately involved in all forms of neuropathology,
7 including
various types of neurodegeneration. Alzheimer’s disease (AD
8)
isthemostcommonformofneurodegeneration,whichresultsin
severe and irreversible cognitive decline and dementia.
9 The
loss of neurones and synaptic connectivity in AD has been
speciﬁcally linked to the extracellular deposition of amyloid
b-peptide (Ab), with its progressive aggregation to form
insoluble amyloid plaques as well as intracellular Tau neuro-ﬁ-
brillary tangles.
10,11 Microglial activation in AD has been
discovered two decades ago,
12 and activated microglia
are generally believed to be involved in AD-associated
inﬂammatory response,
13 although the precise role of microglial
cells in AD pathogenesis remains to be elucidated and
characterised
14,15
Some studies have shown that activated microglia con-
tribute to neurodegeneration in AD, either via the chronic
secretion of pro-inﬂammatory peptides
16 or by being involved
in the formation of Ab plaques.
17 However, other reports have
suggested a neuroprotective role of microglia in AD through,
for example, Ab clearance.
15,18 At any rate the concentration
of activated microglia in the vicinity of Ab plaques is routinely
observed,
19–22 although the changes in the resting microglia
population in AD remain unknown.
The aim of the present study was to quantify the density
of resting and activated microglia in the CA1 subﬁeld of the
hippocampus in a triple transgenic mouse model (3 Tg-AD)
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23,24 3 Tg-ADmiceexpress
mutant versions of the human presenilin 1 (PS1M146V) and tau
(P301L) genes on a Tg2576 (amyloid precursor protein
(APP)Swe mutant) background, resulting in the formation of
both Ab plaques and neuroﬁbrillary tangles with a similar
spatialandtemporaldistributiontothatobservedinhumanAD
patients. We provide further evidence for the localisation of
reactive microglia to amyloid plaques within CA1; in addition,
we discovered a signiﬁcant increase in the density of resting
microglial cells, which precedes the massive activation of
microglia.
Results
The populations of resting and activated microglia were
analysed in the hippocampi of 3 Tg-AD mice at three
different ages, at 9, 12 and 18 months. Importantly, at
9 months of age the hippocampal tissue of these animals is
virtually plaque-free, whereas the plaque load becomes
substantial at 12 and 18 months.
23,25,26 The resting microglial
cells were identiﬁed by speciﬁc staining with tomato lectin,
27
whereasactivatedmicrogliawerestainedwithMac-1antibody
raised against CD11b.
28
In the dorsal hippocampus, and more speciﬁcally within
the CA1 of both non-Tg and 3 Tg-AD mice, we observed
two different phenotypes of microglial cells (Figures 1 and 2).
The resting, tomato-lectin immunoreactive (TL-IR) cells
were characterised by a small cell body equipped with thin-
to-medium ramiﬁed processes extending to the surrounding
neuropil (Figure 1b and c), typical of resting microglia.
Occasionally, resting microglia were also observed in the
vicinity of dense deposits that were likely to be potential Ab
aggregates (data not shown). The other type of microglial
cells, which were reactive for Mac-1, showed enlarged cell
bodies from which processes with an enlarged and thicker
appearance emanated (Figure 2d and e), thus being
consistent with a reactive phenotype. Reactive microglia were
predominant in 3 Tg-AD mice (Figure 2a–c).
Resting microglia in AD. There was no difference between
the morphological characteristics of TL-IR resting microglia
in either 3 Tg-AD or the respective non-Tg controls,
independent of the age (Figure 1b and c). The area density
(Sv, number/mm
2) of resting microglia was signiﬁcantly larger
in 3 TG-AD animals when compared with the control at all
ages (Po0.01; Figure 1a). When the Sv was compared
between 3 Tg-AD and non-Tg controls, it was signiﬁcantly
larger at 9 (105%, P¼0.058), 12 (54%, P¼0.0198) and
18 (131%, P¼0.0116; Figure 1a) months. In non-Tg
animals, ageing (9–18 months) did not affect the Sv of
resting microglia, whereas in 3 Tg-AD animals we found
a clear age-dependent increase in Sv between 9 and 18
months (F2,13¼7.078; P¼0.0106).
Activated microglia in AD. We found no change in the
typical morphology of Mac-1-IR reactive microglia in all age
groups in both control and 3 Tg-AD animals. In control
animals the area density of Mac-1-IR was stable at all ages,
showing no signiﬁcant changes at 9, 12 and 18 months
(Figure 2a). In contrast, in the 3 Tg-AD mice the area
density of Mac-1-IR (total activated microglial cells) was
signiﬁcantly increased throughout the whole extension of CA1
(Figure 2b and c) at 12 months (111%; P¼0.0311) and 18
months (88%; P¼0.0330), but showed only a non-signiﬁcant
rise at 9 months (55.44%, P¼0.1163). The Mac-1 activated
microglia were almost exclusively localised in close proximity
to Ab plaques and/or aggregates (Figure 2f–h). The cell
bodies of these reactive microglial cells were distributed in a
circular shape around the plaque periphery (Figure 2f–h). The
Mac-1-IR activated microglial cells were normally present in
multiple clusters, revealing an active phagocytic activity as
shown by a high degree of co-localisation with Ab (Figure 2f,
g). This phagocytic function was effective in removing the Ab
load, as shown by the presence of small packs of broken Ab
aggregates surrounded by hypertrophic and multiprocess
MAC-1-IR cells (Figure 2h). Reactive microglia were also
Figure 1 Visualisation and quantiﬁcation of resting microglia in the hippocampi
of 3 Tg-AD animals. (a) Bar graph showing the area density of resting microglia
(Sv; number/mm) in the hippocampal CA1 of 3 Tg-AD mice and non-Tg control
mice.(b,c)Brightﬁeldmicrographsshowingthecharacteristicmorphologyofresting
TL-IR microglia with small cell body equipped with thin to medium ramiﬁed
processes extending to the surrounding neuropil in the CA1 subﬁeld of the
hippocampus of 9- and 18-month-old 3 Tg-AD mouse, respectively, which is not
modiﬁed either by age or by Ab amyloid plaques. Scale bar¼5mm
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Cell Death and Diseasepresent around vascular elements that accumulated Ab,w h i c h
is typical of AD-associated angiopathy (Figure 2f).
Discussion
Although it has long been known that activated microglia
are associated with compact Ab plaques,
29 their role in the
development of AD is not completely understood.
2,14
Although numerous studies have attempted to characterise
microglial function in AD, few have aimed to quantify the
changes in the two types of microglia population (resting and
reactive). In the present study, we investigated the changes
in the density of microglial cells in 3 Tg-AD mice, with
particular focus on the CA1 subﬁeld of the hippocampus.
Figure 2 Microglial activation in plaque-infested hippocampal tissue. (a) Bar graph showing the effect of age-related changes on MAC-1-IR reactive microglia within the
CA1 subﬁeld of the hippocampus at 9, 12 and 18 months between non-Tg control and 3 Tg-AD mice. (b, c) Brightﬁeld micrographs showing the increase in MAC-1-IR
reactive microglia (asterisk) in 3 Tg-AD (c) versus non-Tg control mice (b) in the hippocampal CA1. (d, e) High-magniﬁcation micrographs illustrating the characteristic
morphology of reactive microgliawithin theCA1 subﬁeld of the hippocampusof an 18-month-old3 Tg-ADmouse. Reactivemicroglia appearwith most enlargedcell bodies
fromwhichagreaternumberofnumerousprocessesemanated,butwithanenlargedandthicker(arrows)appearance(f,g).ConfocalimagesshowingrecruitmentofMAC-1-
IRmicroglia(green)inthevicinityofAbamyloidplaques(red;f,g)andaggregates(h)intheCA1subﬁeldofthehippocampusofan18-month-old3 Tg-ADmouse.In(f)we
can also observe this reactive microglia surrounding a blood vessel (BV) attaint of Ab deposits. Scale bars: (b, c) 100mm, (d, e)5mm and (f)2 0mm
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Cell Death and DiseaseThe CA1 area was shown to be highly susceptible to Ab
pathology in both human AD patients and 3 Tg-AD mice,
which is also important in the context of memory impairment.
Within the hippocampus the CA1 is the major component of
the Schaffer collateral pathway, acting as a neural conduit
betweenthehippocampalsubﬁelds,subiculumandentorhinal
cortex.
30 As such, neuronal activity in CA1 has been strongly
linked to memory formation, an aspect of cognitive function,
which is typically compromised in AD.
9
We foundthatthe reactivemicroglia was denselypopulated
withregionsofhighAbdeposition,withtheprocessesofmany
of these cells appearing to be in contact with Ab aggregates.
Some microglial cells contained an intracellular deposition of
Ab, thus indicating active phagocytosis. Similar observations
were made in the brains of Tg2576 mice (expressing human
mutated APPswe), in which activated microglia were concen-
trated in close proximity to amyloid plaques.
19 Similarly, the
aggregation of activated microglia around Ab plaques was
shown in vivo in 3–4-month-old double-transgenic mice
expressing a mutant APP and PS1; chronic imaging experi-
ments demonstrated that the number of plaque-associated
microglia increased at the rate of about three cells per plaque
per month.
31
We foundanincreasein activatedmicroglia inthe CA1 area
at 12 and 18 months, which correlates with the age of
the appearance and development of Ab plaques in the
hippocampus of the 3 Tg-AD animal model, even though in
cortical areas they appear as early as at 6 months of
age.
23,25,26
We therefore suggest that the activation of microglia occurs
in response to Ab plaque formation and stabilisation. The
activated microglia surrounded not only the fully formed
plaques but also smaller deposits of Ab (Figure 2h). This
observation may be interpreted in either of two ways: (i) a
resultofplaquedestructionandclearance,or(ii) theformation
of small soluble aggregates before plaque consolidation.
Activated microglia associated with Ab plaques have been
implicatedinthephagocytosisofcerebralAb,
15,18withreports
indicating that these cells may be involved in the stabilisation
or clearance of Ab plaques in the brain.
32 Our results
corroborate these suggestions, as we found the accumulation
of Ab by activated microglia, as shown by MAC-1/Ab double
staining (Figure 2f and g). Incidentally, we did not observe a
substantialactivationofmicroglia atapre- and/orearlyplaque
stage at 9 months of age, indicating that microglial reactivity
does not develop until the plaques are formed and/or con-
solidated. Similarly, a recent longitudinal study using multi-
photon microscopy to image the brains of 5–6-month-old
B6C3-YFP transgenic mice (bearing APPswe and PS1d9x-
YFP genes) has also alluded to this, reporting that microglia
are recruited to Ab plaques only after they have been
formed.
33
Apart from conﬁrming the AD-associated activation of
microglia, we found the disease-speciﬁc increase in the
density of resting microglial cells. To the best of our knowl-
edge, this is the ﬁrst attempt to characterise resting microglia
in the AD. The immunoreactivity against tomato lectin, which
is used as a speciﬁc probe for resting microglia, increased at
all ages in 3 Tg-AD animals, whereas there were no age-
dependent changes in the control brains. An increase in the
densityofrestingmicrogliawasquitesubstantial–thenumber
of cells had roughly doubled. This increase preceded both the
plaque formation and the activation of microglia by extra-
cellular Ab accumulation. The mechanism of microglial
proliferation and the origin of the additional resting microglial
cells remain obscure and require further study. In particular,
we cannot rule out the role for blood-borne macrophages,
which have been shown to migrate across the blood–brain
barrier in response to perivascular amyloid deposition, as well
asthesecretion ofcytokinesandchemoattractantpeptidesby
microglia and astrocytes in these areas.
21,22 Upon entering
the CNS, these cells function as reactive microglia, localising
as phagocytes to amyloid plaques, secreting pro-inﬂamma-
torypeptides and effectively accumulating Ab.
21,34 We cannot
exclude, however, thata similar inﬁltration canstart before the
active inﬂammatory Ab-associated phase; at that stage, the
intruding cells may transform to the resting microglia. All in all,
we may suggest that AD pathology triggers a complex micro-
glial reaction: at the initial stages of the disease the number
of resting microglia increases, as if in preparation for the
ensuing activation in an attempt to ﬁght the extracellular Ab
loadthatischaracteristicoftheterminalstagesofthedisease.
An increase in the density of resting microglia associated
with atrophic changes in astrocytes
26 may also lead to a
remodelling of the glial-related domain structure of the grey
matter (Figure 3). This in turn can affect synaptic connectivity,
because of both reduced astroglial coverage and the possible
synaptolitic effects of multiplied microglia. Thus, early
changes of neuroglia can represent a pathologically relevant
step in the cognitive decline observed at the early stages
of AD.
Several therapeutic strategies have attempted to target
microglia activity as a means of treating AD, each with limited
success. Of these, immunotherapy protocols aimed to
up-regulate the microglial clearance of cerebral Ab,
18,35
whereas an alternative strategy used anti-inﬂammatory
agents to reduce microglial neurotoxicity.
36 These attempts
reﬂect the well-known dichotomy of microglial function, which
may be both neuroprotective and neurotoxic.
2 Nonetheless,
withoutacomprehensiveunderstandingofmicroglialchanges
and roles in AD, and especially the balance between different
stages of microglial activation, these attempts at therapeutic
intervention may continue to be futile. Furthermore, an early
increase in resting microglia, which precedes the Ab plaque
formation, may also have certain diagnostic signiﬁcance.
Materials and Methods
All animal procedures were carried out in accordance with the United Kingdom
Animals (for Scientiﬁc Procedures) Act of 1986 under the license from the Home
Ofﬁce. All efforts were made to reduce the number of animals by following the 3R’s.
Mice. The procedure for generating 3 Tg-AD mice has been described
previously.
23,24 Brieﬂy, human APP cDNA harbouring the Swedish mutation
(KM670/671NL) and human P301L mutated four-repeat Tau were co-microinjected
intosingle-cellembryosofhomozygousPS1M146Vknock-inmice.Thebackground
of the PS1 knock-in mice is a hybrid 129/C57BL6. The control mice used were also
from the same strain and genetic background as the PS1 knock-in mice, but they
express the endogenous wild-type mouse PS1 gene. All 3 Tg-AD and control
mice were obtained by crossing homozygous breeders. Mice were independently
grouphousedandkeptonadaily12-hlight–darkcycledarkschedule.Allmicewere
given ad libitum access to food and water.
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Cell Death and DiseaseFixation and tissue processing. Male 3 Tg-AD and their respective
non-transgenic controls (non-Tg) of different ages (9, 12 and 18 months of age;
n¼3–5) were anaesthetised with an intraperitoneal injection of sodium
pentobarbital. Brains were ﬁxed by perfusion through the aortic arch with 3.8%
acrolein (TAAB, UK) in a solution of 2% paraformaldehyde and 0.1M phosphate
buffer (PB), pH 7.4, followed by 2% paraformaldehyde. The brains were removed
from the cranium and cut into 4–5mm coronal slabs of tissue containing the entire
rostrocaudal extent of the SVZ. These slabs were subsequently post-ﬁxed for
30min in 2% paraformaldehyde before sectioning at 40–50mm on a vibrating
microtome (VT1000, Leica, Milton Keynes, UK). To remove excess reactive
aldehyde groups, sections were treated with 1% sodium borohydride in PB for
30min. Coronal vibratome sections at levels  1.58mm/ 2.46mm (hippocampus)
posterior to the bregma were selected for immunohistochemistry according to the
mouse brain atlas of Paxinos and Franklin.
37
Antibody and reagents. A polyclonal afﬁnity-puriﬁed rat antiserum raised
against CD11b (Mac-1; Serotec, Kidlington, UK) was used for the determination of
activated microglial cells. A Mac-1 antibody was used to selectively label activated
microglia in our brain sections. Mac-1 has a speciﬁc afﬁnity to the microglial surface
membrane receptor CD11b, which is highly expressed by reactive microglia,
28 and
is therefore routinely used as a speciﬁc marker of reactive microglia. Although we
identiﬁed a small amount of low-intensity labelling for resting microglia in our tissue
sections, the staining was observed to be largely speciﬁc for reactive microglia. For
the identiﬁcation of b-amyloid (Ab) plaques, we used a monoclonal mouse
antiserum that reacts with abnormally processed isoforms, as well as precursor
forms of Ab, recognizing an epitope within amino acids 3–8 (EFRHDS; anti-Ab
6E10 [SIG-39320]; Signet Laboratories, Dedham, MA, USA). To assess for non-
speciﬁc background labelling or cross-reactivity between antibodies derived from
different host species, a series of control experiments were performed. Omission of
primaryand/orsecondaryantibodiesfromtheincubationsolutionsresultedinatotal
absence of target labelling (data not shown). Resting microglia were identiﬁed by
using biotinylated tomato lectin (Sigma-Aldrich, Poole, UK). Tomato lectin is a
sugar-binding glycoprotein that has a speciﬁc afﬁnity for poly-N-acetyl lactosamine
residues occurring on the surface membranes of microglia and endothelial cells.
27
Immunohistochemistry. To optimise the detection of Mac-1 and tomato
lectin (resting microglia), sections through the hippocampus of all control and
transgenic animals were processed by using the highly sensitive avidin–biotin
peroxidise complex method.
38 For this procedure, vibratome sections were ﬁrst
incubated for 30min in 0.5% bovine serum albumin in 0.1M Tris-buffered saline
(TBS),pH7.6,containing0.25%TritonX-100tominimisenon-speciﬁclabelling.The
tissue sections were then incubated for 48h at room temperature in 0.1% bovine
serum albumin in TBS containing 0.25% Triton X-100 that in turn contained either
rat anti-Mac-1 (1mg/ml) or biotinylated tomato lectin (2mg/ml). Brieﬂy, following
repeated washing in TBS, sections for Mac-1 were incubated in 1:200 dilutions of
biotinylated donkey anti-rat IgG followed by avidin-biotin complex (Elite kit; Vector
Laboratories, Peterborough, UK). For tomato lectin identiﬁcation the sections were
directlyincubatedintheavidin-biotincomplex.Theperoxidasereactionproductwas
visualised by incubation in a solution containing 0.022% 3,30-diaminobenzidine
(Aldrich, Gillingham, UK) in TBS containing 0.003% H2O2 for 6min.
For the detection and determination of Mac-1-positivecells and their relationship
with Ab senile plaques, we used dual indirect immunoﬂuorescence labelling. The
sections were incubated for 48h at room temperature in a primary antibody cocktail
containing (1) mouse anti-b amyloid monoclonal antibody (Ab; 1:2000; Covance,
Emeryville, CA, USA) and (2) rat anti-Mac-1 (1:30.000; Sigma, Saint Louise, MO,
USA) simultaneously. Subsequently, Ab and Mac-1 were detected in a sequential
manner on the same sections by incubation with rhodamine (TRITC)-conjugated
goat anti-mouse and FITC-conjugated goat anti-rat (Invitrogen, Paisley, UK) IgG,
respectively.Finally,sectionswererinsedwith0.1MTSfor 30min andpermanently
mounted in an aqueous medium (Vectashield; Vector Laboratories).
Cell counting. The Sv (number/mm
2) of Mac-1 (Mac-1-IR) and TL-IR cells was
determined from four non-consecutive coronal sections, separated by at least
80mm, which were taken from representative sections of the dorsal hippocampus.
The ImageJ 1.41 image processing software was used to outline and determine the
areaofCA1,byperformingthequantiﬁcation;thenthenumberofeitherMac-1-IRor
TL-IR was determined. Cells were counted and images obtained using a Nikon
E-80i wideﬁeld microscope and a confocal microscope (Leica SP5 upright). To
ensure consistency and reproducibility, samples were counted blindly.
Statistical analysis. Data were expressed as mean±S.E. Analysis of
variance(one-way)was usedto examinedifferencesinthemean numberof Mac-1-
IR and TL-IR cells in the 3 Tg-AD and non-Tg animals during ageing, followed by
a Bonferroni’s post-hoc test where appropriate. Whenever two groups were
compared, an unpaired t-test was applied.
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